Summary of Key Information:

Reporting Period (Quarter/Year): Quarter ended 30 June 2026

Nature of Filing / Announcement: Outcome of Board Meeting - Approval of Unaudited Financial Results (Standalone and Consolidated)

Audit Opinion:

Clean limited review report issued by Deloitte Haskins & Sells LLP. No qualifications or modifications noted.

Key Financial Highlights [Rs. in lakhs]:

Consolidated Results:

Revenue from Operations: 9,417.85 (Q1 FY27) vs 10,527.34 (Q4 FY26) vs 7,175.61 (Q1 FY26)

Total Income: 9,517.08 (Q1 FY27) vs 11,143.55 (Q4 FY26) vs 7,323.24 (Q1 FY26)

Net Profit/(Loss) after tax: (401.70) (Q1 FY27) vs 373.99 (Q4 FY26) vs (187.49) (Q1 FY26)

EPS (Basic): (0.75) (Q1 FY27) vs 0.76 (Q4 FY26) vs (0.38) (Q1 FY26)

Other Equity: Not specified for current quarter

Standalone Results:

Revenue from Operations: 9,304.83 (Q1 FY27) vs 10,285.37 (Q4 FY26) vs 7,142.77 (Q1 FY26)

Total Income: 9,403.38 (Q1 FY27) vs 10,901.23 (Q4 FY26) vs 7,290.33 (Q1 FY26)

Net Profit/(Loss) after tax: (387.55) (Q1 FY27) vs 328.21 (Q4 FY26) vs (169.19) (Q1 FY26)

EPS (Basic): (0.72) (Q1 FY27) vs 0.67 (Q4 FY26) vs (0.35) (Q1 FY26)

Paid-up equity share capital: 5,354.90 (face value of Rs. 10/- each)

Other equity: 23,285.18 (revaluation reserve: Rs. Nil)

Expense Breakdown (Consolidated):

Cost of materials consumed: 4,381.61

Employee benefits: 1,918.37

Finance costs: 364.34

Depreciation and amortisation: 537.22

Other expenses: 3,307.80

Tax Expense (Consolidated):

Total tax credit: (155.60)

Current Tax: 0.02

Deferred Tax: (155.62)

Segment-wise Performance:

The Group is principally engaged in a single business segment which is "pharmaceuticals". There is no separate reportable segment as per Ind AS 108 - Operating Segments.

Corporate Actions:

Not Specified

Other Significant Information:

Consolidation includes: ZIM Laboratories Limited (Parent), ZIM Laboratories FZE, Sharjah (Subsidiary), ZIM Health Technologies Limited, India (Subsidiary), SIA ZIM Laboratories Limited, Latvia (Subsidiary), ZIM Thinorals Private Limited, India (Subsidiary), ZIMTAS PTY Limited, Australia (Subsidiary), ZIM Scientific Office LLC, Dubai (Step-Down Subsidiary)

The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures for the year ended 31 March 2026 and year to date figures upto 31 December 2025.